Baxter International (BAX) – Analysts’ Weekly Ratings Updates

A number of research firms have changed their ratings and price targets for Baxter International (NYSE: BAX):

• 2/26/2025 – Baxter International is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “buy” rating and a $42.00 price target on the stock.
• 2/24/2025 – Baxter International was upgraded by analysts at Argus from a “hold” rating to a “buy” rating.
• 2/21/2025 – Baxter International had its price target lowered by analysts at JPMorgan Chase & Co. from $38.00 to $36.00. They now have a “neutral” rating on the stock.
• 2/20/2025 – Baxter International is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $39.00 price target on the stock.

Baxter International Stock Down 0.2 %

NYSE:BAX traded down $0.07 on Tuesday, reaching $34.80. 4,423,166 shares of the stock traded hands, compared to its average volume of 5,066,746. The company has a market capitalization of $17.80 billion, a price-to-earnings ratio of -27.18, a PEG ratio of 0.93 and a beta of 0.61. The company has a current ratio of 1.43, a quick ratio of 1.09 and a debt-to-equity ratio of 1.31. Baxter International Inc. has a 12 month low of $28.33 and a 12 month high of $44.01. The company’s fifty day simple moving average is $31.35 and its 200 day simple moving average is $34.05.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.06. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. The business had revenue of $2.75 billion during the quarter, compared to analyst estimates of $2.67 billion. Equities analysts predict that Baxter International Inc. will post 2.48 EPS for the current fiscal year.

Baxter International Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Friday, February 28th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.95%. Baxter International’s dividend payout ratio is presently -53.13%.

Institutional Trading of Baxter International

Large investors have recently made changes to their positions in the stock. Dodge & Cox boosted its holdings in shares of Baxter International by 13.0% in the fourth quarter. Dodge & Cox now owns 50,377,294 shares of the medical instruments supplier’s stock worth $1,469,002,000 after buying an additional 5,779,100 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Baxter International by 22.3% in the fourth quarter. Bank of New York Mellon Corp now owns 15,359,040 shares of the medical instruments supplier’s stock worth $447,870,000 after buying an additional 2,803,920 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Baxter International by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 12,446,939 shares of the medical instruments supplier’s stock worth $362,006,000 after buying an additional 290,279 shares during the last quarter. Thompson Siegel & Walmsley LLC boosted its holdings in shares of Baxter International by 35.1% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 2,548,215 shares of the medical instruments supplier’s stock worth $74,306,000 after buying an additional 662,042 shares during the last quarter. Finally, Sound Shore Management Inc. CT purchased a new position in shares of Baxter International in the fourth quarter worth approximately $72,450,000. 90.19% of the stock is currently owned by institutional investors.

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.